H.C. Wainwright to Neutral and lowered its price target to $22 from $45. The firm continues to believe the EZH2 inhibitor is an active anti-tumor agent, however, after two years in the clinic it still is unable to tell whether they are dealing with a targeted agent, what the optimal indications could be, and how vulnerable this agent would be to competition. H.C. Wainwright's analyst struggles to see any real value drivers over the next 9-12 months and for shares to be choppy until possibly when it reports data from the DLBCL/FL Phase 2 cohorts next year.